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Abstract 
Protection against SARS-CoV-2 and SARS-related zoonotic coronaviruses with pandemic 
potential is urgently needed. To evaluate immunization strategies, we made nanoparticles 
displaying the receptor-binding domain (RBD) of only SARS-CoV-2 (homotypic nanoparticles) or 
co-displaying the SARS-CoV-2 RBD along with RBDs from animal betacoronaviruses that 
represent threats to humans (mosaic nanoparticles; 4-8 distinct RBDs). Mice immunized with 
RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and 
neutralization responses, confirming increased immunogenicity from multimerization. Mosaic-
RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous 
RBDs compared to sera from immunizations with homotypic SARS-CoV-2–RBD-nanoparticles 
or antibodies from COVID-19 convalescent human plasmas. Moreover, sera from mosaic-RBD–
immunized mice neutralized heterologous pseudotyped coronaviruses equivalently or better 
after priming than sera from homotypic SARS-CoV-2–RBD-nanoparticle immunizations, 
demonstrating no loss of immunogenicity against any particular RBD resulting from co-display. 
Thus, a single immunization with mosaic-RBD-nanoparticles provides a potential strategy to 
simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses. 
 
 
SARS-CoV-2, a newly-emergent betacoronavirus, resulted in a global pandemic in 2020, 
infecting millions and causing the respiratory disease COVID-19 (1, 2). Two other zoonotic 
betacoronaviruses, SARS-CoV and MERS-CoV, also resulted in outbreaks within the last 20 
years (3). All three viruses presumably originated in bats (4), with SARS-CoV and MERS-CoV 
adapting to intermediary animal hosts before jumping to humans. SARS-like viruses circulate in 
bats and serological surveillance of people living near caves where bats carry diverse 
coronaviruses demonstrated direct transmission of SARS-like viruses with pandemic potential 
(5), suggesting a pan-coronavirus vaccine is needed to protect against future outbreaks and 
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pandemics. In particular, the WIV1 and SHC014 bat strains are thought to represent an ongoing 
threat to humans (6, 7). 
 
Most current SARS-CoV-2 vaccine candidates include the spike trimer (S), the viral protein that 
mediates target cell entry after one or more of its receptor-binding domains (RBDs; S1B 
domains) adopt an “up” position to bind a host receptor (Fig. 1A). The RBDs of human 
coronaviruses SARS-CoV-2, SARS-CoV, HCoV-NL63, and related animal coronaviruses (WIV1 
and SCH014) utilize angiotensin-converting enzyme 2 (ACE2) as their host receptor (1, 8, 9), 
while other coronaviruses use receptors such as dipeptidyl peptidase 4 (10) or sialic acids (11, 
12). Consistent with its function in viral entry, S is the primary target of neutralizing antibodies 
(13-22), with many targeting the RBD (14-18, 21-26). 
 
Multivalent display of antigen enhances B-cell responses and can provide longer-lasting 
immunity than monovalent antigens (27, 28), thus protein-based vaccine candidates often 
involve a nanoparticle that enables antigen multimerization. Many nanoparticles and coupling 
strategies have been explored for vaccine design (29), with a “plug and display” strategy being 
especially useful (30, 31). In this approach, a virus-like particle fused to a SpyCatcher protein is 
covalently conjugated to a purified antigen tagged with a 13-residue SpyTag (29-32). The 
SpyCatcher-SpyTag system was used to prepare multimerized SARS-CoV-2 RBD or S trimer 
that elicited high titers of neutralizing antibodies (33, 34). Although promising for a SARS-CoV-2 
vaccine, large coronavirus reservoirs in bats suggest future cross-species transmission (6, 7, 
35), necessitating a vaccine that could protect against emerging coronaviruses as well as 
SARS-CoV-2. Here we used plug and display to prepare SpyCatcher003-mi3 nanoparticles (31) 
simultaneously displaying SpyTagged RBDs from human and animal coronaviruses to evaluate 
whether mosaic particles can elicit cross-reactive antibody responses. We show that mice 
immunized with homotypic or mosaic nanoparticles produced broad binding and neutralizing 
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responses, in contrast to plasma antibodies elicited in humans by SARS-CoV-2 infection. 
Moreover, mosaic nanoparticles showed enhanced heterologous binding and neutralization 
properties against human and bat sarbecoviruses compared with homotypic SARS-CoV-2 
nanoparticles.  
 
We used a recent study of sarbecovirus RBD receptor usage and cell tropism (36) to guide our 
choice of RBDs for co-display on mosaic particles. From the 29 RBDs that were classified into 
distinct clades (clades 1, 2, 1/2, and 3) (36), we identified diverse RBDs from SARS-CoV, WIV1, 
and SHC014 (clade 1), SARS-CoV-2 (clade 1/2), Rs4081, Yunnan 2011 (Yun11), and Rf1 
(clade 2), and BM48-31 (clade 3), of which SARS-CoV-2 and SARS-CoV are human 
coronaviruses and the rest are bat viruses originating in China or Bulgaria (BM48-31). We also 
included RBDs from the GX pangolin clade 1/2 coronavirus (referred to here as pang17) (37), 
RaTG13, the bat clade 1/2 virus most closely related to SARS-CoV-2 (38), RmYN02, a clade 2 
bat virus from China (39), and BtKY72, a Kenyan bat clade 3 virus (40). Mapping of the 
sequence conservation across selected RBDs showed varying degrees of sequence identity 
(68-95%), with highest sequence variability in the ACE2 receptor-binding motif (Fig. 1A-C; fig. 
S1). We chose 8 of the 12 RBDs for making three types of mosaic nanoparticles: mosaic-4a 
(coupled to SARS-2, RaTG13, SHC014, and Rs4081 RBDs), mosaic-4b (coupled to pang17, 
RmYN02, RF1, and WIV1 RBDs), and mosaic-8 (coupled to all eight RBDs), and compared 
them with homotypic mi3 particles constructed from SARS-CoV-2 RBD alone (homotypic SARS-
2). RBDs from SARS, Yun11, BM-4831, and BtKY72, which were not coupled to mosaic 
particles, were used to evaluate sera for cross-reactive responses.  
 
SpyTag003-RBDs were coupled to SpyCatcher003-mi3 (60 potential conjugation sites) (41) to 
make homotypic and mosaic nanoparticles (Fig 2A). Particles were purified by size exclusion 
chromatography (SEC) and analyzed by SDS-PAGE, revealing monodisperse SEC profiles and 
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nearly 100% conjugation (Fig. 2B,C). Representative RBDs were conjugated to SpyCatcher003-
mi3 with similar or identical efficiencies (fig. S2), suggesting that mosaic particles contained 
approximately equimolar mixtures of different RBDs. 
 
We immunized mice with adjuvant plus either soluble SARS-CoV-2 spike trimer (SARS-2 S), 
nanoparticles displaying only SARS-2 RBD (homotypic SARS-2), nanoparticles co-displaying 
RBDs (mosaic-4a, mosaic-4b, mosaic-8), or unconjugated nanoparticles (mi3). IgG responses 
were evaluated after prime or boost immunizations (Fig. 3A) by ELISA against SARS-2 S (Fig. 
3B) or a panel of RBDs (Fig. 3C-F; fig. S3). Sera from unconjugated nanoparticle-immunized 
animals (black in Fig. 3, fig. S3) showed no responses above background. Anti-SARS-2 S trimer 
and anti-SARS-2 RBD serum responses were similar (Fig. 3B,C), demonstrating that antibodies 
elicited against RBDs can access their epitopes on SARS-2 S trimer. We also conducted in vitro 
neutralization assays using pseudotyped viruses for strains known to infect 293TACE2 target cells 
(SARS-CoV-2, SARS, WIV1 and SHC104). Neutralization and ELISA titers were significantly 
correlated (fig. S4), thus suggesting ELISAs are predictive of neutralization results when 
pseudotyped neutralization assays were not possible due to unknown viral entry receptor usage.  
 
Mice immunized with soluble SARS-2 S trimer (brown bars) showed no binding or neutralization 
except for autologous responses against SARS-2 after boosting (Fig. 3C-F). By contrast, sera 
from RBD-nanoparticle–immunized animals (red, green, yellow, and blue bars) exhibited binding 
to all RBDs (Fig. 3C-F; fig. S3A) and neutralization against all four strains after boosting (Fig. 
3C-E), consistent with increased immunogenicities of multimerized antigen on nanoparticles 
versus soluble antigen (27, 28). Homotypic SARS-2 nanoparticles, but not soluble SARS 2 
trimer, induced heterologous responses to zoonotic RBDs and neutralization of heterologous 
coronaviruses (Fig. 3D-F). To address whether co-display of SARS-2 RBD along with other 
RBDs on mosaic-4a and mosaic-8 versus homotypic display of SARS-2 RBD (homotypic SARS-
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2) diminished anti-SARS-2 responses, we compared SARS-2–specific ELISA and neutralization 
titers for mosaic versus homotypic immunizations (Fig. 3C): there were no significant differences 
in IgG anti-SARS-2 titers for animals immunized with homotypic (red in Fig. 3C) versus mosaic 
nanoparticles (green and blue in Fig. 3C). Thus there was no advantage of immunization with a 
homotypic RBD-nanoparticle versus a mosaic-nanoparticle that included SARS-2 RBD in terms 
of the magnitude of immune responses against SARS-2.  
 
We next compared serum responses against matched RBDs (RBDs present on an injected 
nanoparticle; gray horizontal shading) versus mismatched RBDs (RBDs not present on injected 
nanoparticle; red horizontal shading) (Fig. 3; fig. S3). Although SARS-2 RBD was not presented 
on mosaic-4b, antibody titers elicited by mosaic-4b immunization (yellow) were not significantly 
different than titers elicited by matched nanoparticle immunizations (homotypic SARS-2 (red), 
mosaic-4a (green), and mosaic-8 (blue)), and sera from boosted mosaic-4b–immunized mice 
neutralized SARS-2 pseudovirus (Fig. 3C). In other matched versus mismatched comparisons, 
sera showed binding and neutralization of SHC014 and WIV1 regardless of whether these 
RBDs were included on the injected nanoparticle (Fig. 3D), underscoring sharing of common 
epitopes among RBDs (Fig. 1A). Demonstrating advantages of mosaic versus homotypic SARS-
2 nanoparticles, sera from mosaic-8–immunized mice bound SHC014 and WIV1 RBDs 
significantly better after the prime than sera from homotypic SARS-2–immunized mice and 
retained better binding to SHC014 RBD after boosting (Fig. 3D). Moreover, mosaic-8–immunized 
and boosted sera were 7-44–fold more potent than sera from homotypic SARS-2–immunized 
animals in neutralizing SHC014 and WIV1 (Fig. 3D). Mosaic-8 included SHC014 and WIV1 
RBDs, again suggesting that combining RBDs on a mosaic nanoparticle does not diminish the 
immune response against a particular RBD, as also suggested by ELISAs against Rs4081 and 
RaTG13 (fig. S3A,B). 
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To address whether RBD-nanoparticles elicited antibodies against totally mismatched strains, 
we evaluated sera for binding to SARS, Yun11, BM-4831, and BtKY72 RBDs (Fig. 3E,F) and 
neutralization of SARS (Fig. 3E). Against these RBDs, we found significantly higher and more 
cross-reactive antibody responses for mosaic immunizations compared with homotypic SARS-2 
immunizations: e.g., mosaic-8–primed and boosted animals showed significantly higher titers 
against SARS RBD than sera from homotypic SARS-2–immunized mice (Fig. 3E). After the 
prime, sera from the homotypic SARS-2–immunized animals did not neutralize SARS, whereas 
the mosaic-4b and mosaic-8 sera were neutralizing (Fig. 3E), perhaps facilitated by these 
nanoparticles including WIV1 RBD, which is related by 95% sequence identity to SARS RBD 
(Fig. 1C). After boosting, SARS-2 and mosaic-4a sera were also neutralizing, although titers 
were ~4-fold lower than for mosaic-8–immunized animals (Fig. 3E). ELISA titers against other 
mismatched RBDs (Yun11, BM-4831, BtKY72) were significantly higher for sera collected after 
mosaic-8 priming compared to sera from homotypic SARS-2 priming, and heightened binding 
was retained after boosting (Fig. 3F). Thus mosaic nanoparticles, particularly mosaic-8, induce 
higher antibody titers against mismatched RBDs than homotypic SARS-2 nanoparticles, again 
favoring the co-display approach for inducing broader anti-coronavirus responses, especially 
after a single prime. 
 
We investigated the potential for cross-reactive recognition using flow cytometry to ask whether 
B-cell receptors on IgG+ splenic B-cells from RBD-nanoparticle–boosted animals could 
simultaneously recognize RBDs from SARS-2 and Rs4081 (related by 70% sequence identity) 
(Fig. 1C; fig. S5). Whereas control animals were negative, all other groups showed B-cells that 
recognized SARS-2 and Rs4081 RBDs simultaneously, suggesting the existence of antibodies 
that cross-react with both RBDs (fig. S5E). 
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To compare antibodies elicited by RBD-nanoparticle immunization to antibodies elicited by 
SARS-CoV-2 infection, we repeated ELISAs against the RBD panel using IgGs from COVID-19 
plasma donors (42) (Fig. 4). Most of the convalescent plasmas showed detectable binding to 
SARS-2 RBD (Fig. 4A). However, binding to other sarbecovirus RBDs (RaTG13, SHC014, 
WIV1, Rs4081 and BM-4831) was significantly weaker than binding to SARS 2 RBD, with many 
human plasma IgGs showing no binding above background (Fig. 4B-G). In addition, although 
convalescent plasma IgGs neutralized SARS-CoV-2 pseudoviruses, they showed weak or no 
neutralization of SARS, SHC014, or WIV1 pseudoviruses (Fig. 4H). These results are consistent 
with little to no cross-reactive recognition of RBDs from zoonotic coronavirus strains resulting 
from SARS-CoV-2 infection in humans. 
 
In conclusion, we confirmed that multimerization of RBDs on nanoparticles enhances 
immunogenicity compared with soluble antigen (33, 43) and further showed that homotypic 
SARS-2 nanoparticle immunization produced IgG responses that bound zoonotic RBDs and 
neutralized heterologous coronaviruses after boosting. By contrast, soluble SARS-2 S 
immunization and natural infection with SARS-CoV-2 resulted in weak or no heterologous 
responses in plasmas. Co-display of SARS-2 RBD along with diverse RBDs on mosaic 
nanoparticles showed no disadvantages for eliciting neutralizing antibodies against SARS-CoV-
2 compared with homotypic SARS-2 nanoparticles, suggesting mosaic nanoparticles as a 
candidate vaccine to protect against COVID-19. Furthermore, compared with homotypic SARS-
2 RBD particles, the mosaic co-display strategy demonstrated advantages for eliciting 
neutralizing antibodies against zoonotic sarbecoviruses, thus potentially also providing 
protection against emerging coronaviruses with human spillover potential. Importantly, 
neutralization of matched and mismatched strains was observed after mosaic priming, 
suggesting a single injection of a mosaic-RBD nanoparticle might be sufficient in a vaccine, 
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greatly simplifying large-scale immunizations. Since COVID-19 convalescent plasmas showed 
little to no recognition of coronavirus RBDs other than SARS-CoV-2, COVD-19–induced 
immunity in humans may not protect against another emergent coronavirus. However, the 
mosaic nanoparticles described here could be used as described and/or easily adapted to 
present RBDs from newly-discovered zoonotic coronaviruses. Since these types of RBD-
nanoparticles retain immunogenicity after lyophilization (33), they could be easily stored for 
widespread use. Thus this modular vaccine platform could provide protection from SARS-CoV-2 
and potential future coronavirus pandemics resulting from emergent zoonotic sarbecoviruses. 
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Figure legends 
Figure 1. Properties of RBDs chosen for this study. (A) Left: Structure of SARS-CoV-2 S trimer 
(PDB 6VXX) with one RBD (dashed circle) in an “up” position. Middle and right: Sequence 
conservation of 12 RBDs calculated by the ConSurf Database (49) plotted on a surface 
representation of the RBD structure (PDB 7BZ5). (B) Summary of properties of the viral strains 
from which the 12 S protein RBDs were derived. (C) Heat map showing percent amino acid 
sequence identities between the 12 RBDs.  
 
Figure 2. Construction of RBD nanoparticles. (A) Left: SpyTagged RBDs were attached to 
SpyCatcher-mi3 to make a homotypic particle (SARS-2 RBD-mi3) and three mosaic particles 
(mosaic-4a, mosaic-4b, and mosaic-8). (B) SEC profile showing separation of RBD 
nanoparticles and free RBD proteins. (C) SDS-PAGE of RBD-coupled nanoparticles, free RBD 
proteins, and uncoupled SpyCatcher003-mi3 particles (SC3-mi3). 
 
Figure 3. RBD nanoparticles induce cross-reactive IgG responses in immunized mice. Red and 
gray rectangles below ELISA and neutralization data represent mismatched strains (red; the 
RBD from that strain was not present on the immunized particle) or matched strains (gray; the 
RBD was present on the immunized particle). (A) Immunization schedule. (B-F) Mice were 
immunized with soluble SARS-CoV-2 S trimer (SARS-2 S; brown bars), or the following 
nanoparticles: homotypic SARS-2 (red), mosaic-4a (green), mosaic-4b (yellow), mosaic-8 (blue), 
or unconjugated SpyCatcher003-mi3 (mi3; black). ELISA data from serum IgG responses to 
SARS-2 spike trimer (B) or RBDs (C-F) shown as area under the curve (AUC). For C-E, 
neutralization potencies are presented as half-maximal inhibitory dilutions (ID50 values) of sera 
against the pseudoviruses from the indicated coronavirus strains. Dashed horizontal lines 
correspond to the lowest dilution representing the limit of detection. Each dot represents serum 
from one animal, with means and standard deviations for vaccinated cohorts represented by 
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rectangles (mean) and horizontal lines (SD). Significant differences between groups linked by 
horizontal lines are indicated by asterisks and p-values. NS=not significant. (B-F) Neutralization 
and/or binding data for serum IgGs for recognition of (B) SARS-2 spike trimer, (C) SARS-2 RBD 
and SARS-2 pseudovirus, (D) SHC014 and WIV1 RBDs and corresponding pseudoviruses, (E) 
SARS RBD and SARS pseudovirus, (F) Yun 11, BM-4831, and BtKY72 RBDs.  
 
Figure 4. IgGs from convalescent COVID-19 plasma (18, 24) show little to no cross-reactive 
responses. (A-F) Plasma IgG responses were evaluated by ELISA (data shown as binding 
curves with plasma names (18) listed) against RBDs from (A) SARS-2, (B) RaTG13, (C) 
SHC014, (D) WIV1, (E) Rs4081, and (F) BM-4831. Data points are plotted as the mean and 
standard deviation of duplicate measurements. IOMA, an anti-HIV-1 IgG (50), was used as a 
control. (G) ELISA results from panels A-F presented as area under the curve (AUC), where 
each dot represents one plasma sample, with means and standard deviations represented by 
rectangles (mean) and horizontal lines (SD). Significant differences between groups linked by 
horizontal lines are indicated by asterisks and p-values. (H) IC50 values for pseudotyped 
neutralization assays using IgGs from COV7, COV21, and COV72 plasmas (18) (evaluated at 
top concentrations of 1500 µg/mL) against the indicated strains. Mean=arithmetic mean IC50; 
SD=standard deviation.  
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Methods  
Expression of RBD and S proteins. Mammalian expression vectors encoding the RBDs of 
SARS-CoV-2  (GenBank MN985325.1; S protein residues 319-539) and SARS-CoV S 
(GenBank AAP13441.1; residues 318-510) with an N-terminal human IL-2 or Mu phosphatase 
signal peptide were previously described (42). Expression vectors were constructed similarly for 
RBDs from the following other sarbecovirus strains: RaTG13-CoV (GenBank QHR63300; S 
protein residues 319-541), SHC014-CoV (GenBank KC881005; residues 307-524), Rs4081-
CoV (GenBank KY417143; S protein residues 310-515), pangolin17-CoV (GenBank QIA48632; 
residues 317-539), RmYN02-CoV (GSAID EPI_ISL_412977; residues 298-503), Rf1-CoV 
(GenBank DQ412042; residues 310-515), W1V1-CoV (GenBank KF367457; residues 307-528), 
Yun11-CoV (GenBank JX993988; residues 310-515), BM-4831-CoV (GenBank NC014470; 
residues 310-530), BtkY72-CoV (GenBank KY352407; residues 309-530). Two versions of each 
RBD expression vector were made: one including a C-terminal hexahistidine tag (G-HHHHHH) 
and SpyTag003 (RGVPHIVMVDAYKRYK) (41) (for coupling to SpyCatcher003-mi3) and one 
with only a hexahistidine tag (for ELISAs). Biotinylated SARS-CoV-2 and Rs4081 RBDs were 
produced by co-transfection of Avi/His-tagged RBD expression plasmids with an expression 
plasmid encoding an ER-directed BirA enzyme (kind gift of Michael Anaya, Caltech). RBD 
proteins were purified from transiently-transfected Expi293F cell (Gibco) supernatants by nickel 
affinity and size-exclusion chromatography (42). Peak fractions corresponding to RBDs were 
identified by SDS-PAGE and then pooled and stored at 4˚C. A trimeric SARS-CoV-2 
ectodomain with 6P stabilizing mutations (44) was expressed and purified as described (24). To 
prepare fluorochrome-conjugated streptavidin-tetramerized RBDs, biotinylated SARS-2 and 
Rs4081 RBDs were incubated with streptavidin-APC (eBioscienceTM) and streptavidin-PE 
(ThermoFisher), respectively, overnight at 4oC at a 1:1 molar ratio of RBD to streptavidin subunit.  
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Preparation of human plasma IgGs. Plasma samples collected from COVID-19 convalescent 
and healthy donors are described in (18). Human IgGs were isolated from heat-inactivated 
plasma samples using 5-mL HiTrap MabSelect SuRe columns (GE Healthcare Life Sciences) 
as described (24).  
 
Preparation of RBD-mi3 nanoparticles. SpyCatcher003-mi3 particles were prepared by 
purification from BL21 (DE3)-RIPL E coli (Agilent) transformed with the pET28a His6-
SpyCatcher-mi3 gene (Addgene) as described (45). Briefly, cell pellets from transformed 
bacterial were lysed with a cell disruptor in the presence of 2.0 mM PMSF (Sigma). Lysates 
were spun at 21,000xg for 30 min, filtered with a 0.2 µm filter, and mi3 particles were isolated by 
Ni-NTA chromatography using a pre-packed HisTrapTM HP column (GE Healthcare). Eluted 
particles were concentrated using an Amicon Ultra 15 mL 30K concentrator (MilliporeSigma) 
and purified by SEC using a HiLoad® 16/600 Superdex® 200 (GE Healthcare) column 
equilibrated with 25 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.02% NaN3 (TBS). SpyCatcher-mi3 
particles were stored at 4°C and used for conjugations for up to 1 month after filtering with a 0.2 
µm filter or spinning at 21,000xg for 10 min. 
 
Purified SpyCatcher-mi3 was incubated with a 1.2-fold molar excess (RBD to mi3 subunit) of 
purified SpyTagged RBD (either a single RBD for making homotypic SARS-CoV-2 RBD 
particles or an equimolar mixture of four or eight RBDs for making mosaic particles) overnight at 
room temperature in TBS. Conjugated mi3 particle were separated from free RBDs by SEC on a 
Superose 6 10/300 column (GE Healthcare) equilibrated with PBS (20 mM sodium phosphate 
pH 7.5, 150 mM NaCl). Fractions corresponding to conjugated mi3 particles were collected and 
analyzed by SDS-PAGE. Concentrations of conjugated mi3 particles were determined using a 
Bio-Rad Protein Assay.  
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Immunizations. Animal procedures and experiments were performed according to protocols 
approved by the IACUC. Experiments were done using 4-6 week old female Balb/c mice 
(Charles River Laboratories), with 5 animals each for cohorts immunized with soluble SARS-
CoV-2 S or SpyCatcher-mi3, and 10 animals each for remaining cohorts (Fig 3A). 
Immunizations were carried out with intraperitoneal (ip) injections of either 5 µg of conjugated 
RBD (calculated as the mass of the RBD, assuming 100% efficiency of conjugation to 
SpyCatcher-mi3), 5 µg of soluble SARS-CoV-2 S, or 6 µg of unconjugated SpyCatcher-mi3, in 
100 µL of 50% v/v AddaVaxTM adjuvant (Invivogen). Animals were boosted 4 weeks after the 
prime with the same quantity of antigen in adjuvant. Animals were bled every 2 weeks via tail 
veins, and then euthanized 8 weeks after the prime (Day 56, 57) and bled through cardiac 
puncture. Blood samples were allowed to clot at room temperature in MiniCollect® Serum and 
Plasma Tubes (Greiner), and serum was harvested, preserved in liquid nitrogen, and stored at -
80˚C until use.  
 
Sera for ELISAs were collected at Day 14 (Prime) and Day 42 (Boost). Sera for neutralization 
assays were collected at Day 28 (Prime) and Day 56 (Boost) (Fig. 3, fig. S3). 
 
ELISAs. 10 µg/ml of a purified RBD (not SpyTagged) in 0.1 M NaHC03 pH 9.8 was coated onto 
Nunc® MaxiSorp™ 384-well plates (Sigma) and stored overnight at 4oC. Plates were washed 
with Tris-buffered saline with 0.1% Tween 20 (TBS-T) after blocking with 3% bovine serum 
albumin (BSA) in TBS-T for 1 hr at room temperature. Mouse serum was diluted 1:100 and then 
serially diluted by 4-fold with TBS-T/3% BSA and added to plates for 3 hr at room temperature. 
A 1:50,000 dilution of secondary HRP-conjugated goat anti-mouse IgG (Abcam) was added 
after washing for 1 hr at room temperature. Plates were developed using SuperSignal™ ELISA 
Femto Maximum Sensitivity Substrate (ThermoFisher) and read at 425 nm. Curves were plotted 
and integrated to obtain the area under the curve (AUC) using Graphpad Prism 8.3 assuming a 
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted November 17, 2020. ; https://doi.org/10.1101/2020.11.17.387092doi: bioRxiv preprint 
 21 
one-site binding model with a Hill coefficient (Fig. 3; fig. S3). We also calculated EC50s and 
endpoint titers, which were determined using the dilution that was at or below the mean + 2 x 
the standard deviation of the plate control (no primary serum added) for ELISA binding data (fig. 
S3C,D). AUC calculations were used as they better capture changes in maximum binding (46). 
Statistical significance of titer differences between groups were calculated using Tukey’s 
multiple comparison test using Graphpad Prism 8.3.  
 
Neutralization assays. SARS-CoV-2, SARS, WIV1, and SHC014 pseudoviruses based on HIV 
lentiviral particles were prepared as described (18, 47) using genes encoding S protein 
sequences lacking C-terminal residues in the cytoplasmic tail: 21 amino acid deletions for 
SARS-CoV-2, WIV1, and SHC014 and a 19 amino acid deletion for SARS-CoV. For 
neutralization assays, four-fold serially diluted sera from immunized mice were incubated with a 
pseudotyped virus for 1 hour at 37˚C. After incubation with 293TACE2 target cells for 48 hours at 
37˚C, cells were washed twice with phosphate-buffered saline (PBS) and lysed with Luciferase 
Cell Culture Lysis 5x reagent (Promega). NanoLuc Luciferase activity in lysates was measured 
using the Nano-Glo Luciferase Assay System (Promega). Relative luminescence units (RLUs) 
were normalized to values derived from cells infected with pseudotyped virus in the absence of 
serum. Half-maximal inhibitory dilutions (ID50 values) were determined using 4-parameter 
nonlinear regression in AntibodyDatabase (48). Statistical significance of titer differences 
between groups were calculated using Tukey’s multiple comparison test of ID50s converted to 
log10 scale using Graphpad Prism 8.3. 
 
Flow cytometry. B-cell analysis using flow cytometry was carried out as described (45). Briefly, 
single-cell suspensions were prepared from mouse spleens using mechanical dissociation, and 
red blood cells were removed using ACK lysing buffer (Gibco). The white blood cell preparation 
was enriched for IgG+ B-cells using the negative selection protocol in a mouse memory B-cell 
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isolation kit (Miltenyi). The following commercial reagents were used to stain enriched 
splenocytes: CD4-APC-eFluor 780 (clone: RM4-5), F4/80-APC-eFluor 780 (clone: BM8), CD8a-
APC-eFluor 780 (clone: 53-6.7), Ly-6G-APC-eFluor 780 (clone: RB6-8C5), IgM- APC-eFluor 
780 (clone: II/41) (Thermo Fisher Scientific), CD19-FITC (clone: 6D5) (Biolegend), IgG1 BV421 
(clone: X40) and IgG2 BV421 (clone: R19-15) (BD Bioscience). SARS-2 RBD-APC and Rs4081 
RBD-PE for used to identify antigen-specific B-cells. Cell viability was analyzed with Fixable 
Viability Stain 700 (BD Bioscience). Stained cells were analyzed with a SY3200 Cell Sorter 
(Sony) configured to detect 6 fluorochromes. 2,000,000 events were collected per sample and 
analyzed via FlowJo software (TreeStar).  
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Supplementary Figure legends 
 
Figure S1. Alignment of RBD sequences used for making mosaic particles. Sequences shown 
are for the RBDs of SARS-CoV-2 (SARS-2, GenBank: MN985325.1), RaTG13 (QHR63300), 
SHC014 (RsSHC014, KC881005), Rs4081 (KY417143), PCoV_GX-P5L (pang17) (QIA48632), 
RmYN02 (GSAID EPI_ISL_412977), Rf1 (DQ412042), WIV1 (KF367457), SARS-CoV 
(AAP13441.1), Yun11 (Cp/Yunnan2011, JX993988), BM-4831 (BM48-31/BGR/2008, 
NC014470), and BtKY72 (KY352407). 
 
Figure S2. RBDs from the eight sarbecovirus S proteins conjugate equivalently to SpyCatcher-
mi3. (A) SEC profiles showing separation of RBD nanoparticles and free RBD proteins. (B) 
SDS-PAGE of RBD-coupled nanoparticles, free RBD proteins, and uncoupled SpyCatcher003-
mi3 particles (SC3-mi3). 
 
Figure S3. Day 14 serum IgG responses to RBDs evaluated by ELISA shown as area under the 
curve (AUC) from mice immunized with soluble SARS-CoV-2 S trimers (SARS-2 S) or RBDs on 
nanoparticles (homotypic SARS-2, mosaic-4a, mosaic-4b, mosaic-8, or unconjugated 
SpyCatcher003-mi3 (mi3)). Each dot represents serum from one animal, with means and 
standard deviations represented by rectangles (mean) and horizontal lines (SD). RBDs from 
strains that were not present on an immunized particle or were present on an immunized 
particle are indicated by red and gray rectangles, respectively, below the ELISA data. Significant 
differences between groups linked by horizontal lines are indicated by asterisks and p-values. 
NS=not significant. (A,B) Binding of serum IgGs to (A) Rs4081 and (B) RaTG13 RBDs. (C,D) 
Comparison of ELISA data for serum binding to selected RBDs presented as AUC, endpoint 
titers, midpoint titers, or binding curves. Day 14 serum IgG responses to (C) SARS-2 or (D) 
SARS RBDs evaluated by ELISA shown as AUC (left), endpoint titers (middle left), midpoint 
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(EC50) titers (middle right), or binding curves (right). For AUC, each dot represents serum from 
one animal, with means and standard deviations represented by rectangles (mean) and 
horizontal lines (SD). For endpoint and midpoint titers, each dot represents serum from one 
animal, with geometric means and geometric standard deviations represented by rectangles 
(mean) and horizontal lines (SD). Binding curves are shown with data points representing the 
mean and SD of duplicate measurements fit to a binding model (see Methods) for animals 
immunized with mosaic-8 and homotypic SARS-2.  
 
Figure S4. Correlation of ELISA and neutralization titers. Spearman correlation coefficients (rS) 
and p-values shown for graphs of anti-RBD ELISA titers (AUC) versus pseudovirus 
neutralization ID50 values; significance indicated as asterisks. (A) SARS-2. (B) SARS. (C) 
SHC014. (D) WIV1.  
 
Figure S5. Antigen-specific IgG+ B-cell analysis of splenocytes isolated from animals immunized 
with mosaic-RBD nanoparticles. (A) Flow cytometry gating strategy for characterizing RBD-
specific IgG+ B-cells isolated from splenocytes. Anti-CD4, anti-CD8, anti-F4/80, anti-Ly6G, and 
anti-IgM were used in the dump to remove T-cells, macrophages, and IgM+ B-cells. Antigen-
specific IgG+ B-cells were isolated using labeled anti-CD19 and anti-IgG antibodies, and probed 
for binding RBD with a pair of fluorophore-conjugated RBD tetramers (SARS-2 RBD and 
Rs4081 RBD). (B) Complete flow cytometry analysis for antigen-specific IgG+ splenocytes 
isolated from animals immunized with mosaic-RBD particles. The 4-way gate shown for each 
animal separates each population of RBD single-positive and double-positive cells and was 
used for the % antigen-specific populations shown in panels C-E. Q1 represents the Rs4081 
RBD+ population, Q2 represents the Rs4081 RBD+ / SARS-2 RBD+ population, Q3 represents 
the SARS-2 RBD+ population, and Q4 represents the RBD- population. (C-E) Percent single-
positive (SP) and double-positive (DP) cells for the indicated groups. Significant differences 
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between groups linked by horizontal lines are indicated by asterisks and p-values. NS = not 
significant. (C) Percent SARS-2 RBD+ B-cells within the IgG+ B-cell population. (D) Percent 
Rs4081 RBD+ B-cells within the IgG+ B-cell population. (E) Percent SARS-2 RBD+ / Rs4081 
RBD+ B-cells within the IgG+ B-cell population. 
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